ACE2-overexpressing Stable Cell Lines

Based on the recent research progress, ACE2 is considered as the main host cell receptor of the recently emerging SARS-CoV-2. It plays a crucial role in the entry of the virus into the cell to cause infection, thus ACE2 related study has important implications for understanding SARS-CoV-2 pathogenesis and transmissibility. Creative Biolabs has adopted the proprietary technology to integrate human ACE2 into the chromosomes of different cells to form a clonal cell line (e.g. ACE2-CHO and ACE2-293T) that stably expresses ACE2 on the cell surface. Our cell line provides an effective tool to customers for further studying the interaction between the receptor ACE2 and COVID-19, explaining the mechanism of virus invasion, and developing drugs and vaccines for treating COVID-19 virus.

Angiotensin Converting Enzyme 2 (ACE2) and SARS-COV-2

Residue 394 (glutamine) in the SARS-CoV-2 receptor binding domain (RBD) corresponds to residue 479 in SARS-CoV and can be recognized by key lysine 31 on the human ACE2 receptor. Further studies even show that SARS-CoV-2 recognizes human ACE2 more efficiently than SARS-CoV, thereby improving the ability of SARS-CoV-2 to spread from person to person. Therefore, it is predicted that SARS-CoV-2 spike protein also has strong binding affinity for human ACE2, which is required for host cell entry and subsequent virus replication. In a mouse model of SARS-CoV-2 infection, overexpression of human ACE2 enhances the severity of the disease, suggesting that virus entry into cells is a critical step. In short, SARS-CoV-2 neurite protein directly binds to ACE2 receptors on the surface of host cells and promotes virus entry and replication. Therefore, studying the action mechanism of ACE2 receptor and COVID-19 virus is of great significance for the development of drugs and vaccines for the treatment of diseases infected by SARS-COV-2.

Potential Therapeutic Approaches to Address ACE2-mediated COVID-19

• Spike protein-based vaccine. Research on ACE2 as SARS-CoV-2 receptor could promote the development of spike protein-based subunit vaccine.
• Inhibition of transmembrane protease serine 2 (TMPRSS2) activity. By interacting with the ACE2 receptor, TMPRSS2 is essential for SARS-CoV-2 entry and virus transmission.
• Blocking ACE2 receptor. The interaction site can be targeted with antibodies or small molecules.
• Delivering excessive soluble form of ACE2. Excessive ACE2 may compete with SARS-CoV-2 for binding and not only neutralize the virus, but also rescue cellular ACE2 activity, thereby negatively regulating the renin-angiotensin system (RAS) and protecting the lungs from harm.

Fig.2 Potential approaches to address ACE2-mediated COVID-19 following SARS-CoV-2 infection. (Haibo, Z. 2020)

ACE2-overexpressing Stable Cell lines

Creative Biolabs is able to provide a variety of stable cell line construction services. Utilizing our gene screening and amplification system, we can generate customized stable cell lines based on genes provided by customers or genes synthesized through our related services.

In order to study the ACE2 of this highly contagious virus SARS-COV-2, Creative Biolabs established a series of stable cell lines that stably express human ACE2. We adopted the proprietary technology to integrate human ACE2 into the chromosomes of cells to form the clonal cell line that stably expresses ACE2 on the cell surface. Our cell line provides an effective tool for further studying the interaction between the receptor ACE2 and COVID-19, explaining the mechanism of virus invasion, and developing drugs and vaccines for treating COVID-19 virus.

If you are interested in our ACE2-overexpressing stable cell line, please feel free to contact us. Our professional team will work with you to determine the best solution for your needs.

Reference

1. Haibo, Z.; et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. 2020 03 March.

For Research Use Only. We do not provide direct services or products for patients.